ASH: AstraZeneca's Calquence, BeiGene's Brukinsa turn heads with new data, putting Imbruvica on notice

Johnson & Johnson and AbbVie’s Imbruvica currently reigns supreme in the previously untreated chronic lymphocytic leukemia (CLL) market. But newer members of its class are threatening, and both put up data over the weekend in other cancer types that might catch the attention of CLL prescribers down the line.